Lakewood-Amedex Biotherapeutics announces annual shareholder meeting

• Lakewood-Amedex Biotherapeutics will hold its annual stockholder meeting virtually on September 22, 2026.
• Shareholders will vote on electing four directors for one-year terms.
• Ballots also cover increasing authorized common shares to 100,000,000 from 12,500,000.
• Proposals include authorizing reverse stock splits up to a cumulative 1-for-20 ratio through September 22, 2027.
• Other items include raising the 2020 equity plan share limit to 400,000, plus auditor ratification for 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lakewood-Amedex Biotherapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-083353), on July 30, 2026, and is solely responsible for the information contained therein.